Antivirals
- PDF / 173,846 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 15 Downloads / 176 Views
1 S
Abnormal liver function: 9 case reports In a retrospective study involving 2234 chronic hepatitis-C patients, who received direct-acting antiviral agent treatment at a hospital in Taiwan during March 2015 to March 2019, eight women and one man aged 52–89 years were described, who developed abnormal liver function during treatment with asunaprevir/daclatasvir, dasabuvir/ombitasvir/paritaprevir/ritonavir or elbasvir/ grazoprevir [dosages, routes, durations of treatments to reactions onsets and outcomes not stated]. Case-1: The 59-year-old man, who had a history of chronic hepatitis-C started receiving asunaprevir/daclatasvir. Previously, he received unspecified interferon. During the treatment he developed abnormal liver function due to the anti-viral treatment. His alanine aminotransferase (ALT) was elevated to 157 U/L and the peak total bilirubin was 1.5 mg/dL. Therefore, he discontinued the asunaprevir/daclatasvir treatment. Case-2: The 52-year-old woman, who had a history of chronic hepatitis-C and liver cirrhosis started receiving asunaprevir/ daclatasvir. Previously, she received unspecified interferon. During the treatment she developed abnormal liver function due to the anti-viral treatment. Her peak ALT was found to be 148 U/L and the peak total bilirubin was 1.7 mg/dL. Therefore, she discontinued the asunaprevir/daclatasvir treatment. Case-3: The 73-year-old woman, who had a history of chronic hepatitis-C and liver cirrhosis started receiving dasabuvir/ ombitasvir/paritaprevir/ritonavir [Viekirax; ombitasvir/paritaprevir/ritonavir/dasabuvir]. Previously, she received unspecified interferon. During the treatment she developed abnormal liver function due to the anti-viral treatment. Her peak ALT was found to be 85 U/L and the peak total bilirubin was 1.7 mg/dL. Therefore, she discontinued the treatment. Case-4: The 89-year-old woman, who had a history of chronic hepatitis-C and liver cirrhosis started receiving dasabuvir/ ombitasvir/paritaprevir/ritonavir [Viekirax; ombitasvir/paritaprevir/ritonavir/dasabuvir]. During the treatment she developed abnormal liver function due to the anti-viral treatment. Her peak ALT was found to be 14 U/L and the peak total bilirubin was 4.7 mg/dL. Therefore, she discontinued the treatment. Case-5: The 80-year-old woman, who had a history of chronic hepatitis-C and liver cirrhosis started receiving dasabuvir/ ombitasvir/paritaprevir/ritonavir [Viekirax; ombitasvir/paritaprevir/ritonavir/dasabuvir]. Previously, she received unspecified interferon. During the treatment she developed abnormal liver function due to the anti-viral treatment. Her peak ALT was found to be 54 U/L and the peak total bilirubin was 4.7 mg/dL. Therefore, she discontinued the treatment. However, she had sustained virological response with the treatment. Case-6: The 64-year-old woman, who had a history of chronic hepatitis-C and liver cirrhosis started receiving dasabuvir/ ombitasvir/paritaprevir/ritonavir [Viekirax; ombitasvir/paritaprevir/ritonavir/dasabuvir]. Previously, she received unspecified inte
Data Loading...
